• Revised plan brings forward reporting of definitive unblinded...

• Revised plan brings forward reporting of definitive unblinded data vs previous planned futility analysis• Australian sites to be incorporated into the trial alongside key centres in Europe•

Trial anticipated to initiate Q42022Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY] (ANP or Company) today announces that it intends to conduct a double-blind, placebo controlled six month dosing trial of ATL1102 followed by a six month open label phase (collectively the ‘Phase IIb’ trial) in non-ambulant boys with Duchenne’s Muscular Dystrophy (DMD)
. The primary endpoint of PUL2.0 will be assessed after six months of treatment (versus 12 months in the Phase IIb/III study).
This follows the Company's previous announcement on 13th July 2022 advising the re-evaluation of its clinical plans for ATL1102 in DMD to focus on the most effective deployment of existing cash reserves and to reduce upfront capital requirements.